Why Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is a biotech force to be reckoned with

Regeneron was founded in 1988 by Dr. Leonard S Schleifer. Dr. Schelifer shared, that the name Regeneron came from “Regenerating neurons, with the word “gene” in the middle”.  The origin of the name further explains that the initial focus of the company was neurobiology. Then in 1990 following the publication of its research in Science, the company announced a collaboration to develop neurotrophic factors.

However, the trials for the company’s neurotrophic factor didn’t go well. That’s when Regeneron refocused its efforts which have led to its success. Regeneron is now a vastly different company from when it started - Regeneron is more of a technology company than a drug company, staying true to its roots as a biotech.

The biotech has developed two high-value technologies platforms that it exploits to discover and develop its assets. The focus of these two platforms is on the discovery & development of antibody or antibody-like assets, which now make up all of Regeneron’s approved products and the bulk of its pipeline programs.

As such, these technology platforms are key assets for the company as it positions them favorably compared to its competitors. Let’s have a look at its two technology platforms.

Technology